骨化三醇_化合物基本信息_供应商_百万化合物信息库

【点击领取】药品品类市场洞察报告！心血管系统药物、消化系统药物、系统用抗感染药物、抗肿瘤药物、眼科药物等（所有报告均有药品品类市场洞察BI系统生成）...
药品品类市场洞察BI系统上线啦，简单快捷完成多维度品类市场分析！医院市场数据、零售市场数据，市场分析模型、可视化BI，助您轻松洞察药品市场脉络，助力精准决策！点击申请试用。

当前位置：首页 > 反馈纠错帮助中心

结构式搜索

骨化三醇

纠错分享

CAS号	32222-06-3
中文别名	钙三醇; 罗钙全; 二羟胆钙化醇; (5Z,7E)-(1S,3R)-9,10-开环胆甾-5,7,10(19)-三烯-1,3,25-三醇
英文别名	Vitamin D3, 1a,25-Dihydroxy-; 1alpha,25-Dihydroxyvitamin D3; 1a,25-Dihydroxyvitamin; 1alpha,25-dihydroxycholecalciferol; (5z,7e)-(1s,3r)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol; 1α,25-dihydroxycholecalciferol; Calcitriol
分子量	416.64
分子式	C₂₇H₄₄O₃
EINECS编号	250-963-8

综合信息查看供应

骨化三醇物理化学性质

外观：白色结晶性粉末
密度：1.06g/cm ³沸点：565℃，760毫米汞柱
熔点：119-121°C
闪点：238.4°C
折射率：1.547
溶解性：不溶性

骨化三醇产品用途

用于慢性肾功能衰竭患者的肾性骨营养不良

骨化三醇毒性

类别：有毒物品
毒性分级：高毒
急性毒性：口服- 大鼠 LD50 0.62 毫克/ 公斤; 口服- 小鼠 LD50: 1.35 毫克/公斤
可燃性危险特性：可燃, 火场排出辛辣刺激烟雾
灭火剂：水, 砂土

骨化三醇储运特性

储存温度：2-8°C
库房通风低温干燥; 与食品分开储运

安全术语

S36/37/39Wear suitable protective clothing, gloves and eye/face protection.
穿戴适当的防护服、手套和护目镜或面具。

S45In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
若发生事故或感不适，立即就医(可能的话，出示其标签)。

风险术语

R26/27/28Very toxic by inhalation, in contact with skin and if swallowed.
吸入、皮肤接触及吞食有极高毒性。

R63Possible risk of harm to the unborn child.
可能有对胎儿造成伤害的危险。

上游原料

2-methyl-1,3-cyclopentanedione1-(phenylsulfanyl)-3-buten-2-one(7aR)-7a-methyl-4-(phenylsulfanyl)-2,3,7,7a-tetrahydro-1H-indene-1,5(6H)-dione(7aR)-7a-methyl-4-(phenylsulfonyl)-2,3,7,7a-tetrahydro-1H-indene-1,5(6H)-dione(3aS,4S,7aR)-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-ol(3aS,4S,7aR)-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-oneethyl 2-[(1S,3aS,4S,7aS)-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]acetate(4-bromo-1,1-dimethylbutoxy)(triethyl)silane; 4-bromo-1,1-dimethylbutyl triethylsilyl etherethyl (2S)-2-[(1S,3aS,4S,7aS)-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]-6-methyl-6-[(triethylsilyl)oxy]heptanoateethyl 2-[(1S,3aS,7aS)-7a-methyl-4-[4-methyl-4-[(triethylsilyl)oxy]pentyl]-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]acetate2-[(1S,3aS,7aS)-7a-methyl-4-[4-methyl-4-[(triethylsilyl)oxy]pentyl]-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]-1-ethanol(1S,3aS,4S,7aS)-1-[(1S)-1,5-dimethyl-5-[(triethylsilyl)oxy]hexyl]-7a-methyloctahydro-1H-inden-4-yl phenyl sulfone; ([(5S)-5-[(1S,3aS,4S,7aS)-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]-1,1-dimethylhexyl]oxy)(triethyl)silane(2S)-2-[(1S,3aS,4S,7aS)-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]-6-methyl-6-[(triethylsilyl)oxy]-1-heptanol2-((3S,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-2-methylenecyclohexylidene)-1-ethanol(1S,3aS,4S,7aS)-1-[(1S)-1,5-dimethyl-5-[(triethylsilyl)oxy]hexyl]-7a-methyloctahydro-1H-inden-4-yl phenyl sulfone; ([(5S)-5-[(1S,3aS,4S,7aS)-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]-1,1-dimethylhexyl]oxy)(triethyl)silane2-((3S,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-2-methylenecyclohexylidene)acetaldehydetert-butyl(dimethyl)silyl (6R,8S)-6-[[tert-butyl(dimethyl)silyl]oxy]-5,6,7,8-tetrahydro-1H-isochromen-8-yl ether; tert-butyl[((6R,8S)-8-[[tert-butyl(dimethyl)silyl]oxy]-5,6,7,8-tetrahydro-1H-isochromen-6-yl)oxy]dimethylsilane1-[(1S,3aS,7aS)-1-[(1S)-1,5-dimethyl-5-[(triethylsilyl)oxy]hexyl]-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-4-yl]-2-((3S,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-2-methylenecyclohexylidene)ethyl acetate(5S)-5-[(1S,3aS,7aS)-4-[1-(acetoxy)-2-((3S,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-2-methylenecyclohexylidene)ethyl]-7a-methyl-4-(phenylsulfonyl)octahydro-1H-inden-1-yl]-1,1-dimethylhexyl acetate(5S)-5-[(1S,3aS,7aS)-4-[(E)-2-((3S,5R)-3,5-bis[[tert-butyl(dimethyl)silyl]oxy]-2-methylenecyclohexylidene)ethylidene]-7a-methyloctahydro-4H-inden-1-yl]-1,1-dimethylhexyl triethylsilyl ether; [((1R,5S)-3-[(Z)-2-((1S,3aS,7aS)-1-[(1S)-1,5-dimethyl-5-[(triethylsilyl)oxy]hexyl]-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene]-5-[[tert-butyl(dimethyl)silyl]oxy]-4-methylenecyclohexyl)oxy](tert-butyl)dimethylsilane